CTOs on the Move

IFM Therapeutics

www.ifmthera.com

 
At IFM Therapeutics, LLC, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body`s first line of immunological response and an essential component of immune function.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ifmthera.com
  • 855 Boylston Street 11th Floor
    Boston, MA USA 02116
  • Phone: 857.327.9903

Executives

Name Title Contact Details

Funding

IFM Therapeutics raised $27M on 06/22/2016
IFM Therapeutics raised $31M on 07/19/2018
IFM Therapeutics raised $55.5M on 12/02/2019

Similar Companies

Telstar

Telstar is a Trevose, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Compass Therapeutics

Compass Therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. Compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. Novel scientific insights are validated and explored deeply inside our labs before Compass pursues the best proprietary combinations of therapeutics into human clinical trials.

Checkerspot

Checkerspot is a design-centric materials company enabling ultra-high performance consumer products.

Xcell Biosciences

Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell`s mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more predictive and iterative therapy development and rapid, highly-controlled clinical cell manufacturing.

Alzheon

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders.